Cencora Stock - Analyst consensus and background on the healthcare distributor
21.06.2026 - 17:38:42 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 15:36 UTC. Details in the imprint.
Cencora (US03073E1055) is one of the largest pharmaceutical distributors in the United States and a key intermediary between drug manufacturers and pharmacies. With no fresh market-moving headlines on Sunday, the focus is on the latest analyst consensus and the company’s longer-term positioning in healthcare distribution.
All news and analysis on Cencora stock
Background reports, price data and regulatory news on Cencora stock can be found in the dedicated topic section on ad-hoc-news.de.
What recent filings show
Cencora was renamed from AmerisourceBergen in 2023 as part of a broader rebranding of the group’s global healthcare services business, including its World Courier logistics unit and consulting operations.
According to its most recent Form 10-K filed with the US Securities and Exchange Commission for the 2024 fiscal year, Cencora reported annual revenue of more than $250 billion, underscoring its role as a top-tier wholesale distributor of branded and generic drugs in North America.
Analyst ratings and consensus
Analyst coverage for Cencora remains broad, with major US and European banks regularly updating their views on the stock. The consensus compiled by financial data providers shows a predominantly positive stance, with most brokerages rating the shares at Buy or Overweight and only a few at Hold.
Target prices gathered across the market typically imply moderate upside from current trading levels, reflecting expectations of stable earnings growth driven by volume increases in pharmaceuticals, ongoing share repurchases and tight cost control. All told, the consensus suggests confidence in the durability of Cencora’s cash flows.
Business model in healthcare distribution
Cencora’s core business is the distribution of branded, specialty and generic pharmaceuticals to pharmacies, hospitals and other healthcare providers, alongside animal health products and related services. The company benefits from high switching costs, scale advantages and long-term contracts with major pharmacy chains.
Beyond basic drug wholesaling, Cencora also offers specialty distribution for complex therapies, patient support programs and consulting services for manufacturers, which provide higher-margin revenue streams and deepen customer relationships across the healthcare value chain.
What the company sells
The product behind the stock is Cencora’s broad portfolio of pharmaceuticals and specialty medicines handled through its distribution network, including branded drugs, generics, oncology therapies and other specialty treatments for hospitals, clinics and pharmacies worldwide.
Where the stock trades today
The shares of Cencora (US03073E1055) trade on the New York Stock Exchange, with the latest available quote around the mid-$200 range in US dollars during recent sessions.
Key facts on Cencora stock
- Company: Cencora Inc.
- ISIN: US03073E1055
- WKN: A3DLDX
- Ticker: COR
- Venue: NYSE
- Price (as of 06/20/2026, 22:00 UTC): 230.00 USD
- Market cap: 45,000,000,000 USD (as of 06/20/2026)
- Sector / Industry: Healthcare / Pharmaceutical Distribution
- Index membership: S&P 500
- Next earnings date: 08/01/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
